MDxHealth (NASDAQ:MDXH) Announces Quarterly Earnings Results

MDxHealth (NASDAQ:MDXH) posted its quarterly earnings results on Thursday. The company reported $999.00 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $999.13, reports. The company had revenue of $29.55 million during the quarter, compared to the consensus estimate of $26.05 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%.

Here are the key takeaways from MDxHealth’s conference call:

• Q4 billable volume was ~38,000 tests (up 62% YoY) with liquid tests up 128%, full-year revenue reported at $107.9M, and 2026 guidance implies roughly 28% growth to $137–$140M driven by unit growth rather than price.
• MDxHealth completed the Q4 transition of Select mdx customers to ExoDx, expects the ExoDx business to contribute $20M+ in 2026, and plans cross-selling after sales integration finishes in Q1.
• Short-term financial pressure: Q4 operating loss rose to $5.3M and net loss to $8.9M, adjusted EBITDA was -$2.1M, and cash on hand was $29M, with management attributing the weakness to integration-related OpEx.
• MDxHealth negotiated an amendment with Exact Sciences that lowers the upcoming earn-out by about $20M and defers full payment by a year, improving near-term liquidity and flexibility.
• Clinical progress: the GPS ProMPT study is complete and the landmark GPS‑ProtecT trial is commencing, which management says could support NCCN guideline adoption and strengthen long-term test adoption.

MDxHealth Trading Up 0.6%

NASDAQ:MDXH traded up $0.02 during mid-day trading on Thursday, hitting $3.55. 343,591 shares of the company’s stock traded hands, compared to its average volume of 88,357. The firm has a market capitalization of $175.73 million, a price-to-earnings ratio of -5.55 and a beta of 1.64. The firm has a 50 day moving average of $3.54 and a two-hundred day moving average of $3.75. MDxHealth has a 12 month low of $1.35 and a 12 month high of $5.33.

Hedge Funds Weigh In On MDxHealth

Institutional investors and hedge funds have recently bought and sold shares of the stock. Intesa Sanpaolo Wealth Management acquired a new position in MDxHealth during the fourth quarter worth $36,000. Lido Advisors LLC acquired a new stake in shares of MDxHealth in the 3rd quarter valued at $48,000. Jefferies Financial Group Inc. bought a new stake in shares of MDxHealth in the 3rd quarter worth about $53,000. Squarepoint Ops LLC acquired a new stake in shares of MDxHealth during the 4th quarter worth about $51,000. Finally, Bank of America Corp DE lifted its holdings in MDxHealth by 5,164.0% during the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock valued at $70,000 after purchasing an additional 14,769 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Lake Street Capital lifted their target price on shares of MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. TD Cowen lifted their price objective on shares of MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. Finally, BTIG Research restated a “buy” rating and set a $7.00 target price on shares of MDxHealth in a report on Tuesday, December 23rd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.75.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.